Ioana, you, us good to has us. always extremely It these an been the joining appreciate on start calls. you productive year and afternoon, We Thank for everyone.
to continued with We clinical our program expand and strategic clinical our which entered deliver and into lead positive pipeline VAC. we and results programs, partnerships, OpRegen OPCX support two
experience. of Board We also of strengthened them appointment the Directors, our healthcare of team overall two to possess both the through and medical individuals significant
whole Lineage the of a medicine rapidly new is in positioning this field. leader on pioneering branch transplant As simultaneously reminder, ourselves based an growing a of cells as and important
cells the If you cord the retina or spinal to spinal cord replacement are to or types is restore approach differentiated to if Simply believe of injury them been need injury. dying, area transplant that need improve cells lost Our directly disease. to eye. transplant has due body to cells to cells provide which into missing, directly damaged we or put, retina to function, you and manufacture cell the are
a our of become all material onetime starting and cell body years more cell for needs. was of characterized be directed In and line of a clinical offer types, than which meaning of which reimplanted, therapy manipulated cell cell cell called manufactured handling our atologous are terms cells case, instead the therapy. source the is line allogeneic, ago. our commercial they and to are established any pluripotent, use they of the are autologous being manufacturing patient advantages each and for from from comprise plus single XXX therapies All Allogeneic can programs a human the removed These in means therapies lines over we and approaches which XX of costs. common provide significant
the As patient for what into people complexity so our and thaw call and after cells thought patients, inject off designed preparing just whole use minutes a often injected formulations can we for the be of solution shelf the single of handling of for that products dose through believe matched We patient complicated instead or in developed preparation customer. lengthy, therapy which autologous cannot and costly therapies the economic allogeneic the steps. options by going being each is be advantages unique a for
as of order an the control, we avoids cell recently, on because risks have noticed types it always which approach rely changes manufacturing of the directed part we in the causing manipulation, genome And to impacted been We our we our and developmental as of only simply Importantly, under ourselves ophthalmology. genetic potential manufacture tightened in conditions field harness the area to into steps in to directed types. called recently differentiation. process, cell With the has turn our the cannot to those order the we differentiation, modify manipulating genome of potentially various pathway have many which you risk. significant of Instead risks final We regulated isn't will of compounds them never biological necessary. make. expose natural desire something
the Our perform cells of the they cells needed job the are to have replacing. attributes
These cancer. may function. help to have dry cord platform our As the to established years large size injury scale, cell over AMD, commercial advantages but are a of spinal house are conditions working potential in production technology developed our we form pursuing, single our additional that and has cell quality not supply also beyond and potentially from only our produce candidates in can our improve and the protocols And our banks the procedures, part any extensively because needs we be product characterized belief establish currently process expanded of for master line control cells market. and both have
encouraging set consider our our of cell and a through own to efficacy and new to will address continue we recent we our strategic quick potentially our additional three alliances. AMD FDA either a dry blindness of turn with intended some cells I'll review on diseases, accomplishments of of lead technology begin approved now for loss with As investigate countries. retina atrophy, is treatments. cause current and on or of applications no to safety OpRegen, the the generate product our the transplants, both caused AMD Dry opportunities to leading data a with developed in is geographic of expectations and progressive treat remainder year. our the by candidate I'll disease
the the is which entire approaches which just mutation, a off inherent but brand to that approaches approach Replacing have treating to a in cell retina this and died only new transplant even Our support or believe that be target a limitations or or patients. are be our reverse the disease We the only to target replace process dysfunctional. risks also may subset prove cells not pathway ones avoids to specific or may pathway, disease certain slow it. able addresses which of halt wrong approach to
were OpRegen, which intend which is advantage X/Xa to helps believe and an data updates with patients periods. we beginning of provides and not this them of how injections. months updates a and data are onetime to these our on that the investors semi clarity local study are that treatment XX we we is do we also study view or continue timelines. convenience our because collected separate open has patients a This frequent different along about typically enthusiasm have interim they five provided the our collected year, and updates. perform so and clinical the visual observation of timelines informative providing interim doing we've Since depending on label can tracking those We providing over a are from appreciate monthly few throughout drugs dates currently in different it's XX as competitors from patients OpRegen, but We be Phase compliance substantial performed the treated the or only that over for required transparency more in just under years, on terms where are contemplated biologics, or monthly traditional anesthesia, also ranging the assessments their minutes developing on less
data informative and this of update half OpRegen coincident data Riemann AMD second For amount six, duration our the we've months corrected think likely with are are example, while changes best with growth presented on pleased through three XXXX and to with effects improved most during Dr. during dry recent were believe Christopher more continues detectable on all treatment. At become conference, four patients in suggest six to grown. or view, the in has meaningful can most to followup. the has enrolled months Eye visual with this Cincinnati our that provided a GA ARVO of post generate update the acuity that from with Consistent most in we as we evidence recent of each with set clinically minimum Institute, responses patients us study with XX the months GA. treatment that We update BCVA
who earlier believe visual the why have Cohorts who legally all in compared in intervention less X This to will affected at better Cohort were clinically also emphasized We is X continue blind severely detecting the acuity data XX of patients X effects. in the increase the first likelihood we through beneficial a final from had that baseline baseline. patients XX to patients
of is same of above months, patients While the X being at acuity at points. the half patients the at untreated XX% baseline eyes the high or while baseline data percentage and notable four is below visual were it were that values assessment at time last collected, still Cohort pretreatment same treated of least eyes their
is cohorts first continue consistent patients improvements structural in among available improvements have vision of Additionally, reported Previously with be time X, were validated at the Cohort collected. X OpRegen magnitude serious [KOL] that we The update patients. overall which or present no last these a X also those clinical a majority through unexpected for X and we overall improvements from Cohort than with prior adverse was life tolerated observed X Cohort continued benefit to which shared adverse be of events. reported larger data the well in quality questionnaire of parameters in the to our with
OpRegen supporting of we material one-time five an of the for to the and in potential determination And treatment. into now designed space. [planar] the study way even agreement data to digital the traditional device this device or of and additional alternative effort pars delivering the of become We make potential use sub-retinal significant compared based device important an also methods and years engraftment totality have the continue help to We considerations, collected data safety, an to via that and the its accessing via exploratory have ease was of standard entered therapeutic to a of date the in option on patient the vitrectomy, performance we the to other OpRegen OpRegen PPV. clinical that a delivering guide deliver party Orbit more role independent PPV. manufacturer investments of as decision. so have third can the for space objective the elected subretinal SDS, extending OpRegen than we our made But We evaluation to further method to with
importance main by to and the parameter. of and improve the and In of a of to encouraged deliver able methods clinical be of flexibility to hope mature. come or expenses and OpRegen economic I to to cells performance need determined within a to One not to party ways patients added was be lapse. this informed which with number we parallel program having we some by procedural of program that for period position those the a evaluate would identified provides that decision, diminishing as device. logistical to treat We which we in opportunities PPV have manufacturer upside the PPV of may with to with will these procedure option which decision factors details share remain with the always continue we delivering to point and I via GA. of procedure. to the third Orbit improve some key greater further use should they to not OpRegen I'm area and further the PPV device include Overall, into this In for party definitive device complexities allowed different benefits our training OpRegen new another Consequently, the close our having outcomes. that a their regulatory, treatment. surgical cohort, out a or this the connection also to separate we might having the continue not enter there the are how ideas agreement and share the elected decision special with improve open and financial additional PPV, to support with to we
all ARVO monitor provide a to data but we by have will continue cut month more in we patients. program, of half, actual month another and since all plan the months on six OpRegen at patients update the the we for ahead next Looking a than preceded And in ARVO off study. update which follow-up the to least
addition moment of the month of The six are amount next will we BCVA of because to for our In important explained the I data this areas OpRegen. a reductions before because for growth to in the FDA the ago. that important GA steps follow-up data we the promising plan indications have we would is retinal safety and restoration discuss period also longer minimum as and the to be data, of engage time in of looking want is with collected development size
moment eye would six-ine measurements GA atrophy always month, in better the the I comparison. month a separation to difficult look. be bit seen visual want I to asked are graphs a slowly increases see as and untrained whether update data of expect next we've the untreated we everyone The upcoming misunderstood. or I I've by all remind the at detect in first use patient’s are take four, of the could acuity vision in patients. just curves believe also light eye in I everyone to that how to baseline. of greater month changes that our I see something three for and is eye of While like a the want GA to a we a is short sometimes grows to large which especially keen been address area that our important, wait very next four why But timeframe remind months, with some
So RPE existing than case. to not in treated us, understand RPE. same that it and comparison every patient’s our at Even the contain more is two because we're more diseased against in may levels found do comparing results baseline work OpRegen points, with a not a eye lipofuscin those important eye of it's balanced a cells
are So our autofluorescence not cells or easily using seen fundus FAS.
a FAF collect to precise existence with detecting imaging is of used order structural OCT to or techniques. is to GA restoration. need from potential But common restoration, Now FAF use see the benefits incapable imaging other data. imaging retinal high tool resolution you conjunction In in
potential don't OpRegen's are we believe graphs So GA and in effect, tables reflecting our fully restoration benefits.
this important not to update know a to point monitoring ours also but a need was is the sometimes techniques but patient. for that Now treat it fairly I the I and changes technical note you not sometimes standard like way a optimized felt how you are you only in newer condition, technologies
tool Fortunately, of part our OCT clinical assessments. imaging sites protocol was at a also always common fairly is and
of more patients for retinas methodology, in independent collecting experts precise drive be dry for to outcomes continue the continue to the deliver or potential handle solutions. ways and our to it, new to these in So ocular anatomical X last treated we we in this now this method evaluating OpRegen Cohort have data. Overall, and to technology of we multiple as optimize using those improved review patient to importantly, access on OCT are fall data and and learn open we have it, we images AMD assisting powerful imaging images of most it, we're about the all learn measure as and will
an continue ongoing We basis. with share also will you to updates on
area from is spinal next into in cervical a paralysis time injury patients an of and high Moving program to spinal cost loss cord are acute and investigational directly oligodendrocyte lifetime to injury. has to cord. transplant specialized injury. estimated patient Acute as injury treat $X cells implantation cord suffer spinal cord surgical no of injury dry spinal currently OPCX, of be for our treatments an been caring there spinal for just cord one motor like as OPCX But GA, of million. approved AMD the function with the FDA
viability a our manufacturing to year, past developed of process, and to Over improvements in in a attributes, production and the other product. expected the OPCX which commercial quality the of significant enhance team leading are new successfully
prior thaw overall scale process to enrollments us scale dose February, relocated to materials number been centers, us a of OPCX The has logistics delivery with spinal trials. significant the This formulation option also we preparation cells announced cord reduce suite steps, in-house Neurgain has minutes our several gives designed We GMP agreement expected because the in lab from a of a support system to use medical will spinal company, a Technologies, which new new cord. in of our costs to a technical conducting a is into hours device been manufacturing reduce respiration. or XX%. hurdle help that enabling and which delivery to This developed to without clinical to believe to novel in formulation next the OR, will few parenchymal allow of the upcoming working to cord to a trial, treatment a spinal and larger just approximately through exclusive access system PSD of investigational administration license preparation at logistics larger In accelerate production steps to spinal where it trial. increase Neurgain reducing the eliminate by we an clinical are recently we the much stopping our OPCX, for and will inject allow enhance patient’s to this
OPCX PSD plan clinical the in to cord and to Our safely both deliver evaluate settings. Neurgain effectively and preclinical is spinal to the
We the from to previous to groundwork Neurgain in OPCX later providing trial, positive interaction. for RMAT for interaction evaluate an that system PSD Phase helping to clinical X/Xa OPCX, stage a for look preparing are forward to upon this and prepare of update June we trial. data our plans clinical All an currently assess FDA the us building is following
this around discuss clinical also we forward. the moving plans OPCX manufacturing ahead, interact the of FDA development the to improvements intend to year process, we’ve well end Looking the as to our as with made
trial our and study clinical plans, this plan. be year. to we on as FDA to in these FDA on commit meetings comparative We position a clinical positioned design, a sometime we Following can as next next trial scale study, our initiate the need agreement to believe interactions assuming large but of reach to be with expect we alignment before registrational path it can a OPCX
are on us position the that a having efforts generating current in putting support the data focused and path. Our to with FDA discussion that
Now cell or and eliminate. system cancer exercised preliminary and the it body’s X we CR results we clinical option to with thereafter, and should immuno-oncology antigen manufacture non-small investigational our I'll specific is cells, potent immune our shelf cancer an therapeutic year, lung to of body, is patients. handpicked vaccine. activity antigen modality presenting and off from proprietary reported deliver or of enhance move cells the in deploy cell established Phase deploy encouraging Last profile which knowledge cells instruct, attack to bring platform an the and the target dendritic safety in mature a cells banks to in-house are increased Cancer which dendritic the in their load consistent VAC VACX, which we've harnessed reemerging tumor cells Research Dendritic UK antigens, to about with the attractive clinical approach cell as dendritic setting. how a on we VACX based UK and most comprised
data Specifically, and potent of with clinical reinforcing VACX responses providing previously. immune conducted induction trials mechanistic VACX us in demonstrated autologous obtained validation
study. coming COVID impacted And CR anticipates will patient be final responsible CR months. by partner, in the while enrolled UK the is UK the Our been restrictions, has that enrollment for
for study quarter the manufacturing our may VACX be completion programs additional the making would trials we focus further for enrollment, which prepare VAC Following fourth Currently, modernizations the year. anticipate data from of and available any this is future on design. improvements provide and we back, around of process competitive will advantages help for to
made the which production work enhancements, Our appeal platform commercial with we increase manufacturing that successful improvements and did like of was directed team OpRegen and on utility just to the and begin OPCX. will VAC the
to of of platform the which cells. the of manufacturing distinguished aim antigenic our immune insert the because And dendritic corporate system. April, implementing any And antigens. trigger a as platform, while nearly as believe This cells use announced antigen, approach this just the us own collaboration we we producing each an VAC for the our partnerships companies’ to advance dendritic that up by enhancement, part enhance first antigens other option platform. is simultaneously in of to large VAC theoretically number cells dendritic number As into one the a our capable also the flexibility are the of example we retaining opens of product to for selected carriers potential limitless carrying specific by you candidates, our strategy I outlined, allowing could VAC
and agreement provided candidate Immunomic and Our it's development VAC glioblastoma the collaborate this and construct tumor manufacturing will novel treatment Lineage with in candidate. from product VAC proprietary our derived a product multiform. associated platform, of antigen clinical generate the targeting will immunotherapy novel by a Immunomic allogeneic cancer Immunomic of for
is the developmental full commercial in payments of clinical up this anticipate independent Immunomic across milestones with receiving development VAC Lineage and advancement and assumes territories. Following entitled program. full and we GMP first to multiple $X product further $XX million responsibility to and agreement connection of million, In alliance, and which commercial in the of indications of and the the year and material, delivery
a will eligible of new the first further on hope promising platform, collaboration it We enter vaccine with royalties of be net we receive into products. helps up platform. many our to This validate VAC future XX% believe and therapeutic VAC also to to partnerships as we to sales represents
independent to the manufacturing capitalizing as provide alliances on well to pipeline partners, our These developments. success. of Lineage's derived new collaboration on success additional cell technology and VAC for is our transplant plan in and without financial diversify oncology burden own leverage as therapies can generate and Our our opportunities with
We extensive Board Jayasuriya, members Directors, of to added clinical and Anula Now and our our Dr. reflect two women affairs. These bring have experience strategic side. in had product position a recently to range Amin as pharmaceutical Board few to for broad the Dr. three corporate and in that both these as or responsibility and Dipti and ensuring to commitment we've regenerative medical research cell first can a leadership a moving appointments I of company's new of development ourselves all to of therapy field perspectives, work progress leader capabilities. clinical rapid expertise provide strengthening of of medicine. we during the our this months valuable made advancing year, Overall, and believe the programs and further the
our Moving next financials. to
and current marketable expected Our cash is into fund XXXX. well securities operations position to our
gross in under on $XX which additional take was currently, change $XX good runway respect case May allowed if plan lot million perspectives an ATM planning course totaling amount position and filed because That of for million week, or program. I we full are but activities. that to us a includes in of in the same program, under operational Our March our preparation XXXX, ATM very a decisions corporate of we perspective believe, supplement for regulatory completed our sales we feedback in proceeds, directions, filed XXXX base different ATM can X, the the operational With program.
first that we received elimination PPP notice the that Lineage March so now reflected been statement of want our us earnings filed However, be also comparative new of about that found debt I informing $XXX,XXX our accounts this periods no morning would QX statements. can in A of these like of loan, sheet conducted have more the spend will today. and our to I X, balance perspective stock our financial XXXX. dated into under our quarter of for to move earlier supplement of view mention for operations can announcement that detailed sales within forgiveness I be confirm XXXX. earlier
shares includes in approximately XX, over and just X.X in shares marketable stock ownership stock which and million remaining of common common XXXX, approximately XXX,XXX Hadasit of cash, equivalents cash Bio-Holdings As our million Ltd. we March of had OncoCyte of securities, $XX.X
proceeds During added million sales we common selling the our our from proceeds and our position shares our marketable first quarter XXXX, of with net to cash million a from $XX.X $XX.X of received program and securities. of net proceeds ATM of of portion
by first As ATM commenced have quarter reduction operations quarter a for in the or was from I The expenses. statement operating approximately $XXX,XXX XXXX sold March under for primarily $XXX,XXX by in to the primarily NIH related to XXXX. $X.X on decrease for XXXX. the year in $XXX,XXX and grant XXXX related activities G&A issued were shares to referenced offering turn primarily were a development next expenses both of XXXX. the first prior decrease to was the $XXX,XXX, first decrease decrease a not any I'll XXXX. earlier, completion approximately expenses. grant same we quarter of income, expenses That the million, a of comprised in approximately X, as of of decrease compared the the driven in was expenses period increase revenues period which same related $XXX,XXX Total and offset in research royalty Operating revenues. are G&A of and Total
first Lineage impacted the for overall XXXX. and our as to rate million for related to important is of in our net loss per net was compared the approximately XXXX value share operations XXXX. The quarter Lineage’s from our between It's million, loss as Hadasit, million from operations reduction $X.X a to period compared $X.X exchange $X investments loss in the of international currency or in by same OncoCyte the loss per or remind for to of fluctuations XXXX loss net $XXX,XXX foreign changes the in variance as share $X.XX quarter and period that was subsidiaries. Our the of investors well same as attributable the first to $X.XX
$XXX,XXX more our moving measure to have relevant programs the clinical While, tend activity cash our roughly would quarter period. expectations. to development as We we Overall, due are expenditures VACX of forward. first our to to and regard of a an the for payment anticipated line UK loss these the with fluctuations immuno-oncology our highest bring early quarter first in performance house from for of option the important, CR exercise Gyroscope utilize in to and of our with back the platform, the for payment year option cash installment our operations was of to $XXX,XXX extension second
For cash to financial say anticipate wrap-up us I are driving to million. the to paths to burn our value. financial to To stability, we the be strategically $X.X our programs position we with XXXX, the forward remainder on while maximize quarterly continue I'll be maintain of pleased approximately clinical section, rate our shareholder that multiple
conclude, So of medical Lineage to helping demonstrate transplants major unmet which cell needs and serious diseases represent opportunities. potential others the allogeneic cell and are conditions, large therapy cure and field market to or of commercial in viability the treat or to allogeneic
and the policy has therapy for test used tools moved in therapies a these public investor patients cell maturity, to manufacturer in are reaching and As methods and positive direction. support
later to and we clinical As convergence trials, accelerate of help we're candidates medicine. our development toward positive position factors advance the stage to to novel to product from of this working commercialization benefit this Lineage branch and
PSD, and June said mind of include milestones, Looking is assess we of key or for in is already interaction to the which expected which events month OpRegen Neurgain RMAT XXXX, have with interim data, remainder next FDA as the forward I to a scheduled number XXXX. which
a OpRegen, completion of We have third FDA currently VACX discuss with clinical We XXXX. anticipated quarter anticipate development of enrollment to is patient the year. this manufacturing plan in the in of completion which meet further of to a ongoing middle testing comparability late OPCX around the and to We're stage process year. expecting improved be of clinical trial this of trial to support study
to that anticipated which opportunity continue end. position We'd to you have the around of evaluate inspire results year. discuss shareholder be the manufacturing have transplant internally to may VAC have. to At proud continue around I FDA we're platform, afternoon expect a support medicine. and for am our We people I We which questions alliances any be ongoing we happen to VACX year With us look Lineage, will cell and OPCX. tumor enjoy, And operator, the or Lineage for report appreciate will appreciate impact that, profound VAC continuing therapy as the from expect of candidates day. and a new millions us end interaction ready to the improvements respond analyst an is which every new we cell this in leader product we antigens. to on make based to partnered to be on from study, opportunities benefiting patients technology and and we we joining particularly the to we of all to identified
